RxDoctor Payments Data

Karishma Patel

Family · Moncks Corner, SCNPI 1932897956

Payments from drug & device makers

$1,886in general payments, 2019–2025

Across 61 payments — averaging $30.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$771
  • Bayer$283
  • Exact Sciences$212
  • Lilly USA, LLC$100
  • Boehringer Ingelheim$90
  • Merck$68
  • plus $361 from 13 others

What the payments were for

  • Food & beverage$1,886100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,886 in reported general payments places this provider in the 75th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$38,501
Medicare patients
95
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol61$51,712
JardianceEmpagliflozin18$31,546
JanuviaSitagliptin Phosphate26$28,068
OzempicSemaglutide27$25,856
EliquisApixaban14$14,960
TrulicityDulaglutide11$12,685
TradjentaLinagliptin11$7,608
Ezetimibe-SimvastatinEzetimibe/Simvastatin11$1,976
Atorvastatin Calcium158$1,762
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,618
Rosuvastatin Calcium47$1,019
Amlodipine Besylate160$960
Losartan Potassium88$822
Celecoxib14$724
Levothyroxine Sodium42$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$771$51,71261 claims
Boehringer IngelheimJardiance, Tradjenta$90$39,15429 claims
MerckJanuvia$68$28,06826 claims
Novo NordiskOzempic$21$25,85627 claims
PfizerEliquis$47$14,96014 claims
Lilly USA, LLCTrulicity$100$12,68511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,248 family providers in South Carolina.

Other family in Moncks Corner

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →